Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma.

被引：0
|
作者：
Maiese, Eric
Graham, Christopher N.
Hawe, Emma
Le Moine, Jean-Gabriel
机构：
[1] Janssen Sci Affairs, LLC, Horsham, PA USA
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] RTI Hlth Solut, Manchester, Lancs, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e20037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20037
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience
    Moustafa, Muhamad Alhaj
    Parrondo, Ricardo
    Abdulazeez, Mays F.
    Roy, Vivek
    Sher, Taimur
    Alegria, Victoria R.
    Warsame, Rahma M.
    Larsen, Jeremy
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Kapoor, Prashant
    Fonseca, Rafael
    Buadi, Francis K.
    Dingli, David
    Hayman, Suzanne R.
    Reeder, Craig B.
    Agrawal, Arshi
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    BLOOD, 2020, 136
  • [42] Daratumumab Improves Progression-Free Survival in Relapsed/Refractory Myeloma
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 915 - 915
  • [43] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [44] Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
    Jakubowiak, Andrzej J.
    Jasielec, Jagoda K.
    Rosenbaum, Cara A.
    Cole, Craig E.
    Chari, Ajai
    Mikhael, Joseph
    Nam, Jennifer
    McIver, Amanda
    Severson, Erica
    Stephens, Leonor A.
    Tinari, Kathryn
    Rosebeck, Shaun
    Zimmerman, Todd M.
    Hycner, Tyler
    Turowski, Agata
    Karrison, Theodore
    Zonder, Jeffrey A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (04) : 549 - 560
  • [45] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Costa, Luciano J.
    Davies, Faith E.
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Hong, Wan-Jen
    Dail, Monique
    Salem, Ahmed Hamed
    Yang, Xiaoqing
    Masud, Abdullah A.
    Munasinghe, Wijith
    Ross, Jeremy A.
    Bueno, Orlando F.
    Kumar, Shaji K.
    Stadtmauer, Edward A.
    BLOOD ADVANCES, 2021, 5 (19) : 3748 - 3759
  • [46] Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Yong, Kwee
    Mikhael, Joseph
    Risse, Marie-Laure
    Asset, Gaelle
    Martin, Thomas
    FUTURE ONCOLOGY, 2020, 16 (02) : 4347 - 4358
  • [47] Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Costa, Luciano J.
    Stadtmauer, Edward A.
    Morgan, Gareth
    Monohan, Gregory
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Mobasher, Mehrdad
    Freise, Kevin J.
    Ross, Jeremy A.
    Pesko, John
    Munasinghe, Wijith
    Gudipati, Saketh
    Mudd, Sarah
    Bueno, Orlando
    Kumar, Shaji K.
    BLOOD, 2018, 132
  • [48] The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
    Jesus F. San-Miguel
    Hermann Einsele
    Philippe Moreau
    Advances in Therapy, 2016, 33 : 1896 - 1920
  • [49] Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups
    Orlowski, Robert Z.
    Moreau, Philippe
    Niesvizky, Ruben
    Ludwig, Heinz
    Oriol, Albert
    Chng, Wee Joo
    Goldschmidt, Hartmut
    Yang, Zhao
    Kimball, Amy S.
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (08): : 522 - +
  • [50] The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
    San-Miguel, Jesus F.
    Einsele, Hermann
    Moreau, Philippe
    ADVANCES IN THERAPY, 2016, 33 (11) : 1896 - 1920
12345